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Background: Induced sputum is a non-invasive method to investigate airway inflammation,
which has been used to assess pulmonary inflammatory diseases. However, this procedure
has not been studied in the context of hematopoietic stem cell transplantation (HSCT).
Methods: We monitored lung function in 182 patients who underwent HSCT and measured
airway inflammation by sputum induction in 80 of them. We prospectively measured FEV1,
FVC, DLCO, KCO, TLC, RV, exhaled nitric oxide (FeNO) as well as sputum cell counts before
and 3, 6, 12, 24 and 36 months after HSCT.
Results: For the whole cohort there was a progressive decrease in TLC, which was significant
after 3 years (p < 0.01). By contrast, there was no change in other lung functions parameters
or in FeNO. Baseline sputum analysis revealed increased neutrophil counts in patients {Median
(IQR): 63% (38e79)} compared to healthy subjects matched for age {Median (IQR): 49% (17e67),
p < 0.001} but there was no significant change in any type of sputum cell counts over the three
years. When comparing myeloablative (MA) vs non-myeloablative (NMA) conditioning, falls in
FEV1, FVC and DLCO, and rise in RV and sputum neutrophils were more pronounced over the
first year of observation in those receiving MA.
Conclusions: There was a progressive loss in lung function after HSCT, featuring a restrictive
pattern. Myeloablative conditioning was associated with early rise of sputum neutrophilsumology-Allergology, Avenue de l’hopital, 13, 4000 Liege, Belgium. Tel.: þ32 4 3664867; fax: þ32 4
s@hotmail.com (C. Moermans).
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Allogeneic hematopoietic stem cell transplantation (HSCT)
has been proposed to treat haematological malignancies
since the 1960s. This type of transplantation requires the
administration of high doses of chemotherapy and/or total
body irradiation (TBI) with the aim of eradicating malignant
cells [1]. In the late 1970, it has been recognized that the
allograft itself confers immune-mediated antileukaemic
effect termed graft-versus-tumour effects. This observa-
tion led to the development of allogeneic HSCT following
non-myeloablative conditioning, in which the burden for
tumour eradication has been shifted from high-dose radio/
chemotherapy towards graft-versus-tumour effects [2].
Unfortunately, pulmonary complications are frequent
after HSCT and are a major cause of post-transplant mor-
tality [3]. They can be classified as infectious or non-
infectious and as early or late depending on whether they
occur before or after 100 days post-transplantation. Among
late and non-infectious complications, bronchiolitis oblit-
erans (BO) is characterized by a rapid and progressive
decrease in expiratory flow rates and a rise in residual
volume. It is admitted that less than 10% of patients
develop BO after HSCT [4e7]. Follow-up of pulmonary
function tests is critical in recognizing its early stages. The
lung function assessment prior to transplantation usually
serves as baseline reference to evaluate the changes in
pulmonary function after HSCT [8].
Induced sputum is a safe method for recovering bron-
chial inflammatory cells. It was shown to be useful in they population PFT: pulmonary f
e material quantity or poor qua
erformed in case of technicalassessment of chronic lung rejection after lung trans-
plantation [9] but it has never been studied in patients
undergoing HSCT. A previous study has shown that broncho-
alveolar lavage neutrophil counts increased during the first
6 months after HSCT in patients without overt pulmonary
complications [10]. Similarly, fraction of exhaled nitric
oxide (FeNO), a non-invasive marker of airway inflamma-
tion, has been used to monitor lung transplantation
rejection [11] but its utility has been poorly assessed after
HSCT.
In an attempt to detect modifications at airway level in
patients who underwent allogeneic HSCT, we performed
pulmonary function tests (PFTs), measured FeNO value, and
induced sputum to look at airway cell composition prior to
HSCT as well as 3 and 6 months, 1, 2 and 3 years after
transplantation.Material and methods
Subjects
We assessed 182 patients who underwent HSCT for hae-
matological diseases at the University Hospital Center of
Liege between January 2006 and October 2011, and who
were reassessed 3 and 6 months, 1, 2 and 3 years later for
their PFTs and FeNO measurement (Fig. 1). Over 1 year
post-transplant, patients were essentially assessed if they
had signs of Graft-Versus-Host-Disease (GVHD). The char-
acteristics of these patients are presented in Table 1.unction test, HSCT: hematopoietic stem cell transplantation;
lity sample (squamous cell fraction > 80%) or sputum induction
staff unavailability or patient poor health status.
Table 1 Demographic characteristics of the patients.
Age (years) 52  13
BMI 25  4
Gender (M/F) 108/74
Tobacco habits (n/ex/cs) 79/65/38
MA/NMA conditioning 49/133
Underlying malignancy
AA 3
AIHA 1
AML 60
MPD 4
CML 3
MDS 20
ALL 9
HL 6
NHL 35
MM 29
CLL 10
PLL 2
Disease risk: low/standard/high 43/92/47
Donor: Unrelated/related 125/57
Patient/donor compatibility
10/10 HLA-identical (allelic level) 80
Other 102
Comorbidities (HSCT-CI score) 2 (0e9)
No. of cells transplanted (106/kg)
CD34þ cells 5.13 (0.04e15.88)
CD3þ cells 318 (0e1216)
Results are expressed as mean  SD except for HSCT-CI score
and number of CD3þ and CD34þ transplanted expressed as Me-
dian (range); BMI Z body mass index, n Z non-smoker,
ex Z ex-smoker, cs Z current smoker, MA Z myeloablative
conditioning, NMA Z non-myeloablative conditioning,
AA Z aplastic anaemia, AIHA Z autoimmune hemolytic
anaemia, AML Z acute myeloid leukaemia,
MPD Z myeloproliferative disease, CML Z chronic myeloid
leukaemia, MDS Z myelodysplastic syndrome, ALL Z acute
lymphoblastic leukaemia, HL Z Hodgkin’s lymphoma,
NHL Z non-Hodgkin’s lymphoma, MM Z multiple myeloma,,
CLL Z chronic lymphocytic leukaemia, PLL Z prolymphocytic
leukaemia.
Lung function and airway inflammation monitoring after HSCT 2073Forty-nine patients underwent a myeloablative-
conditioning regimen (MA), with either 8 gray (Gy) single
dose or 12 Gy fractionated TBI and high-dose chemotherapy
(n Z 43), or high-dose chemotherapy alone (n Z 6). GVHD
prevention consisted in cyclosporine A or tacrolimus with
(nZ 28) or without (nZ 21) short methotrexate (15 mg/m2
on day 1 and 10 mg/m2 on days 3, 6 and 11), with additional
anti-thymocyte globulin (ATG; 45 mg/kg) in 22 of them. One
hundred thirty-three patients underwent non-
myeloablative conditioning (NMA). Two patients did not
receive TBI but a chemotherapy associating fludarabine
(90 mg/m2) and cyclophosphamide (3000 mg/m2). The
others received a conditioning consisting in low-dose TBI
(2 Gy) with (n Z 107) or without (n Z 24) fludarabine
(90 mg/m2). Their immunosuppressive regimen associated
tacrolimus and mycophenolate mofetil (45 mg/kg from day
0 to day 28 in case of HLA-identical sibling donor or day 42
in case of alternative donor).Healthy controls (n Z 116) were recruited by local
advertisement in the hospital. None of them exhibited
respiratory symptoms and all had normal spirometric re-
sults (FEV1 > 80% predicted value) and none had airways
hyperresponsiveness (provocative concentration of meth-
acholine causing a fall in FEV1 of 20% > 16 mg/ml). They
were well matched with patients undergoing HSCT ac-
cording to age (53  8 years) and tobacco habits (non-
smokers: nZ 60; ex-smokers: nZ 38 and current smokers:
n Z 18).
This study was approved by the Ethics Committee of the
Faculty of Medicine at the University of Liege and all sub-
jects gave written informed consent for participation.
Methods
Lung function tests
Each subject underwent a global lung function assessment
using a body box plethysmography (Sensormedics, Vmax
series 22, Viasyhealthcare, Yorba Linda, California, USA)
allowing to measure flow rates, lung volumes and diffusion
capacity according to ATS/ERS standard criteria [12e14].
Spirometry (measure of Forced Expiratory Volume in 1 s:
FEV1 and Forced Vital Capacity: FVC) was performed before
and after 400 mg inhaled salbutamol MDI administered
through a Volumatic. Diffusion for carbon monoxide was
measured by the single breath wash-out technique and
corrected for the blood haemoglobin value. FeNO was
measured using a chemoluminescence analyser (NIOX,
Aerocrine, Stockholm, Sweden) at a flow rate of 50 ml/s, in
accordance with the recommendation of the ATS/ERS task
force [15].
Bronchiolitis obliterans syndrome
The international Society for Heart and Lung Trans-
plantation (ISHLT) proposed a clinical description of BO
termed bronchiolitis obliterans syndrome (BOS) and
defined it by pulmonary function changes (fall of FEV1)
rather than by histology [16]. In our series we assessed the
proportion of patients who satisfied the criteria of BOS
stage > 1 according to this classification (fall of FEV1 > 20%
from baseline).
Sputum induction and processing
The sputum was induced on the same day after completion
of lung function tests by inhalation of hypertonic (4.5%) or
isotonic (0.9%) saline solution according to the post-
bronchodilation FEV1 value, as previously described [17].
Ninety-five patients had a sputum induction. Only 80 pa-
tients out of 95 produced an adequate sample suitable for
cell count analysis (Fig. 1). Failure to get sputum cell count
was explained either by unsuccessful sputum induction or
by poor quality sample (squamous cell fraction greater than
80%). Cell viability was assessed by trypan blue exclusion
and the differential leucocyte count performed on cyto-
spins stained with May-Gru¨nwald-Giemsa on 500 non-
squamous cells.
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Survival analyses were made using the KaplaneMeier
method. The assessment of the distribution normality was
made with the KolmogoroveSmirnov test. Lung function
parameters were normally distributed, expressed as
mean  SD (tables) or  SEM (figures) and compared to
baseline using “t” tests while sputum cell counts and FeNO,
which were not normally distributed, were expressed as
median (IQR) and compared to baseline using Wilcoxon rank
test or ManneWhitney test for paired or unpaired data
respectively. Bonferroni correction was applied to take into
account multiple comparisons, so that only p value < 0.01
at each time point was considered as significant vs baseline.
Statistical analyses were performed with Graph Pad Prism
5.0.
Results
Survival analysis
Overall survival at 1, 2 and 3 years after HSCT were 71%,
63% and 56% respectively (Fig. 2).
BMI
The body mass index (BMI) decreased significantly at day
100 compared to before HSCT (25  4; 22  4; p < 0.0001)
and then begun to increase progressively to return to values
close to baseline at 3 years (24  5). Overall, the BMI
remained within the normal range at each time point.
Lung function
Unpaired comparisons on the whole cohort shows that,
compared to baseline, TLC decreased significantly after 3
years (p < 0.01) (Table 2). In contrast, there was no sig-
nificant change in FEV1, FVC, FEV1/FVC, DLCO, KCO and
FeNO over time compared to baseline, this latter remainingSurvival proportions
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Figure 2 Survival analysis over 3 years of the 182 patients
who underwent HSCT.in accepted normal range [18]. For patients who provided
paired data TLC and RV decreased over time (3 years vs
baseline p < 0.01 for both) while there was no change in
FEV1, FVC, FEV1/FVC, DLCO, KCO and FeNO (Fig. 3). Pa-
tients who underwent MA conditioning generally exhibited
greater falls in FEV1, FVC and corrected DLCO compared to
those receiving NMA conditioning (Fig. 3) (NMA vs MA: FEV1-
D100, p < 0.01; FVC-D100, p < 0.01; D200: p < 0.01; DLCO:
p < 0.01 for D100, D200 and 1 year; RV-D100, p < 0.01).
Among the one hundred thirteen patients who were fol-
lowed up for at least one year, only 4 developed BOS based
on functional criteria (3.5%). Among them, only 3 had a
consistent and persistent fall in lung function indices (2.6%)
(Fig. 4).
Sputum cell counts
Baseline sputum cells counts showed a dominant neutro-
philic inflammation, which was greater than that seen in
healthy subjects matched for age (Fig. 5, p < 0.001). Based
on unpaired comparisons on the whole cohort, there was no
change in total cell counts or in the percentages of
different cell types over time (Table 3). Likewise, for pa-
tients who provided paired data, there was no significant
change in total or in differential cell counts (Fig. 6). How-
ever, when examining the variations according to the con-
ditioning regimen, those receiving MA conditioning showed
a sharp and early rise in the percentage of neutrophils at 3
months compared to baseline (P < 0.01) an observation not
found in those receiving NMA conditioning (Fig. 6). In
addition, the increase in sputum neutrophils at 3 months
was significantly greater after MA compared to NMA
(p < 0.001) and mirrored by a greater fall in macrophages
(p < 0.01).
There was no significant correlation between the change
in lung function indices and the rise in sputum neutrophil
count over the first 12 months even if there was a trend for
an inverse correlation between the change in DLCO and the
change in sputum neutrophil count at 3 months (rZ 0.31;
p Z 0.052).
Predictive factors for survival at one year
There was no significant difference in baseline de-
mographic and functional features between those who
survive at one year and those who died in the first year of
observation (Table 4). Likewise there was no difference
with respect to sputum cells counts.Discussion
The originality of our study is the combination of lung
function assessment, including FeNO, with airway inflam-
mation by measuring sputum cell counts in patients who
underwent HSCT. Our main findings are the intense
neutrophilic airway inflammation at baseline and the pro-
gressive appearance of a restrictive lung function defect
associated with a persistent airway neutrophilic inflamma-
tion after HSCT. By contrast, occurrence of BOS was rare
and only found in 3.5% of patients in our series.
Table 2 Lung function test results over time.
Before HSCT
N Z 182
3 months
N Z 153
6 months
N Z 132
12 months
N Z 113
24 months
N Z 73
36 months
N Z 40
FEV1 pre-BD (% predicted) 89  18 90  18 91  18 89  20 87  17 82  21
FEV1 post-BD (% predicted) 88  17 91  18 91  17 90  22 86  17 83  19
FVC pre-BD (% predicted) 96  17 96  15 98  16 96  19 96  15 91  18
FVC post-BD (% predicted) 96  15 96  16 98  16 97  18 94  17 91  18
FEV1/FVC (%) 76  10 77  10 76  11 76  10 75  10 74  13
FEV1/FVC pots BD (%) 76  10 79  11 77  12 76  12 76  10 76  12
Corrected DLCO (% predicted) 74  25 72  27 72  21 69  19 67  18 65  17
Corrected KCO (% predicted) 90  33 88  28 91  30 88  27 88  24 93  29
TLC (% predicted) 96  14 97  15 96  17 96  16 94  18 87  20*
RV (% predicted) 104  38 108  44 103  41 104  41 100  43 89  35
FENO (ppb) 18 (12e29) 16 (12e27) 20 (15e35) 20 (12e28) 17 (11e22) 14 (11e23)
Results are expressed as mean SD except for FeNO value expressed as median (IQR). FEV1: forced expiratory volume in 1 s; FVC: forced
vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; KCO: gas transfer coefficient; TLC: total lung capacity; RV:
residual volume; BD: bronchodilation; FeNO: exhaled nitric oxide; * <0.01 vs before HSCT; unpaired comparisons.
Lung function and airway inflammation monitoring after HSCT 2075At baseline our patients had flow rates, lung volumes
and FeNO values within the normal range. By contrast, they
showed a slight impairment of diffusing capacity that could
reflect peripheral mismatch between ventilation and
perfusion of the lung as a consequence of past chemo-
therapy and radiotherapy. As far as sputum cells are con-
cerned, patients were characterised at baseline by a
neutrophilic inflammation compared to figures usually seen
in healthy subjects matched for age, although it was to a
lesser extent than that seen in severe COPD [19e21].
Neutrophils are cells that easily and readily migrate into
the lung in response to chemoattractants released upon
airway irritation or injury [22,23]. In our patients, high
sputum neutrophil counts at baseline are likely to reflect
the impact of heavy treatment before HSCT. The persis-
tence of intense neutrophilic airway inflammation after
HSCT is remarkable and could indicate recurrent airways
micro-injuries or bacterial colonisation in fragile patients
because of their immune suppressive treatment. It also
might be a sign of a repair process following aggressive
therapy prior to the transplantation.
Our finding of a restrictive pattern that appears in the
months and years following HSCT is in line with what most
authors reported so far as highlighted in a review article
[24]. However, we have to recognise that, in our study, the
changes remained quite limited in their magnitude. The
restrictive pattern was characterised by a reduced lung
volume including TLC with preserved FEV1/FVC ratio. The
overall decline in lung volume was progressive and maximal
at 3 years. Those receiving NMA conditioning did not show
an early decline in the first year, but displayed a similar
loss in lung volumes at 3 years compared to those receiving
MA conditioning. However, the diffusion capacity was
minimally altered after NMA conditioning (5% fall) even
after 3 years when compared to MA conditioning where the
fall in DLCO was quite marked (exceeding 25% at this time
point).
The reason for the appearance of the restrictive pattern
in our study is unclear. The fact that most of our patients
followed beyond the first year had a GVHD is likely tocontribute to this process as GVHD was shown to favour lung
restriction after HSCT though the underlying mechanism
remains unclear [25]. As BMI remained quite stable we
cannot incriminate a cachectic status to explain the loss of
lung volumes. One could potentially think of skeletal mus-
cle weakness or sequel of recurrent lung injuries likely to
occur in these immuno-compromised patients. On the other
hand thoracic irradiation and cytotoxic chemotherapeutic
agents are recognized factors contributing to the occur-
rence of lung fibrosis that may lead to restriction [24]. This
probably explains the marked alteration in flow rates and
diffusing capacity observed in the first year after HSCT in
those patients receiving myeloablative conditioning.
Only less than 5% of patients developed clinically sig-
nificant BOS, which is in line with a large review on more
than 6000 patients [26], but contrasts with what is gener-
ally observed after lung transplantation where it can occur
in up to 50% of patients surviving beyond 6 months [27].
FeNO has been initially validated as a marker of airway
eosinophilic inflammation in asthma [28,29] with thresh-
olds values of 40e50 ppb being indicative of sputum
eosinophilia >3%. By contrast, it has been recently shown
that FeNO values remained within the normal range in
non-eosinophilic asthma including neutrophilic asthma
[30]. This exhaled biomarker has also been shown to rise
early after lung transplantation complicated by BO [31]
but the value of FeNO after HSCT has been poorly inves-
tigated so far. In our subjects FeNO values, which were
within the normal range [18] at baseline (median 18 ppb),
did not change significantly over time. This is not sur-
prising as the airway inflammation in patients undergoing
HSCT is rather neutrophilic, a feature that amplifies after
transplantation. Our finding contradicts what was recently
reported by Enocson A et al. [32] who followed 68 patients
for 6 months after HSCT. However, in the latter study the
baseline values of FeNO were similar to ours (median
15 ppb) and the change over time, although statistically
significant, was of small magnitude with a median only
reaching 20 ppb at 6 months. On the other hand, Lahzami
et al. did not find any change in FeNO over a one-year
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Figure 3 Changes of lung function indices over time in patients who provided paired data. Results are presented as % of baseline
value  SEM; 100% represent the baseline value. The number of patients at each time point is: 152, 133, 113, 70 and 40 for 3, 6, 12,
24 and 36 months, respectively. For NMA conditioning, the number of patients at each time point is 117, 101, 87, 54 and 32 for 3, 6,
12, 24 and 36 months, respectively. For MA conditioning, the number of patients at each time point is 35, 32, 26, 16 and 8 for 3, 6,
12, 24 and 36 months respectively. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; TLC: total lung capacity; RV:
residual volume; DLCO: diffusing capacity of the lung for carbon monoxide; NMA: non-myeloablative conditioning; MA: myeloa-
blative conditioning. * < 0.01 vs before HSCT; paired comparisons. x < 0.01 vs NMA conditioning; unpaired comparisons.
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Figure 4 Individual changes in FEV1 over time in the 4 pa-
tients who had bronchiolitis obliterans.
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Figure 5 Sputum neutrophil percentage comparisons be-
tween patients before HSCT (n Z 80) and healthy subjects
(n Z 116) matched for age and tobacco status. Unpaired
comparisons.
Lung function and airway inflammation monitoring after HSCT 2077follow-up after HSCT even if the patients showed signs of
small airway dysfunction [33].
High sputum neutrophil counts have been linked to an
irreversible airway obstruction in chronic obstructive pul-
monary disease (COPD) [19] and BO following lung trans-
plantation [34]. Neutrophilic airway inflammation is also
seen in diseases with intense airway bacterial load such as
bronchiectasis [35] and cystic fibrosis [36]. On the other
hand, neutrophils in induced sputum were reported to be
increased in lung transplant recipients even without BO [9].
To the best of our knowledge, we are the first to report on
sputum cell count after HSCT. Even if baseline values of
sputum neutrophil counts were already elevated prior to
HSCT, we found a further rise in sputum neutrophils after
HSCT in those receiving myeloablative conditioning.
Recruitment of neutrophils in the airways is a major event
in case of activation of innate immunity in response to
bacterial and viral infections [37,38] and toxic or pollutant
exposure [39]. The rise in neutrophils during the first year
after MA conditioning may be related to the greater injury
of respiratory mucosal system caused by the intense irra-
diation and chemotherapy. Even if not significant becauseTable 3 Total and differential sputum cell counts over time.
Before HSCT N Z 80 3 months
N Z 65
6 mont
N Z 56
Total cells (106/g) 0.73 (0.34e1.57) 0.94 (0.37e1.97) 0.55 (0
Cell viability (%) 70 (58e80) 69 (57e84) 70 (5
Macrophages (%) 27 (14e43) 27 (14e46) 27 (1
Eosinophils (%) 0.0 (0.0e0.8) 0.0 (0.0e0.8) 0.0 (0
Neutrophils (%) 63 (38e79) 67 (45e81) 65 (4
Lymphocytes (%) 1.8 (0.6e4.4) 1.4 (0.2e4.0) 1.0 (0
Epithelial cells (%) 2.3 (1.0e5.2) 2.7 (0.6e6.0) 2.0 (1
Results are expressed as median (interquartile range); unpaired compof the limited number of subjects assessed at three years in
our study, there was in our study, a trend for a new wave in
sputum neutrophil increase by this time, whose underlying
mechanism may differ from the first wave. Whether the rise
in sputum neutrophils contributes to loss of lung function
indices remains uncertain but neutrophils are a potent
source of proteases endowed with remodelling capabilities.
Our finding at the late time point needs certainly to be
confirmed in a larger cohort as our patient number analysed
at 3 years is limited.
None of the baseline functional and airway inflammation
features had a prognostic value for survival at one year.
This may seem discrepant from previous findings thaths 12 months N Z 39 24 months
N Z 27
36 months
N Z 10
.34e1.98) 0.73 (0.25e3.02) 1.17 (0.30e4.01) 2.91 (0.66e7.10)
3e80) 77 (66e86) 64 (54e83) 74 (65e87)
4e44) 23 (13e42) 16 (9e39) 15 (11e34)
.0e0.9) 0.0 (0.0e0.7) 0.4 (0.0e2.0) 0.0 (0.0e0.4)
8e78) 65 (51e78) 72 (36e84) 74 (55e78)
.5e3.0) 1.5 (0.2e5.0) 1.0 (0.5e2.2) 0.9 (0.4e2.0)
.0e4.8) 1.8 (0.8e4.0) 2.7 (0.7e7.0) 2.7 (0.7e16.3)
arisons.
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Figure 6 Sputum neutrophil and macrophage changes over
time in patients who provided paired data. Results are pre-
sented as mean of % sputum neutrophils or macrophages
changes GSEM. For clarity reason, SEM were removed for NMA
and MA conditioning lines; the number of patients at each time
point is: 45, 35, 24, 12 and 5 for 3, 6, 12, 24 and 36 months,
respectively. For NMA conditioning, the number of patients at
each time point is 35, 25, 20, 8 and 4 for 3, 6, 12, 24 and 36
months, respectively. For MA conditioning, the number of pa-
tients at each time point is 10, 10, 4, 4 and 1 for 3, 6, 12, 24
and 36 months, respectively; NMA: non-myeloablative condi-
tioning; MA: myeloablative conditioning. * < 0.01 vs before
HSCT; paired comparisons. x < 0.01, xx < 0.001 vs NMA con-
ditioning; unpaired comparisons.
Table 4 Difference in baseline demographic and func-
tional features between patients who survived at one year
and those who died in the first year of observation.
Baseline parameter Patients who
died before
1 year;
N Z 52
Patients who
did not die
before 1 year;
N Z 130
P value
Age 54  13 52  13 0.30
BMI 24  3 25  5 0.52
NMA/MA
conditioning
34/18 99/31 0.14
Gender: F/M 22/30 52/78 0.87
Tobacco habits
(n/ex/cs)
22/20/10 57/45/28 0.87
FEV1 (% predicted) 87  18 90  17 0.19
FVC (% predicted) 94  16 97  16 0.33
FEV1/FVC 75  10 76  9 0.30
TLC (% predicted) 95  16 97  13 0.44
RV (% predicted) 103  39 104  37 0.94
DLCO (% predicted) 77  28 72  24 0.24
KCO (% predicted) 94  35 88  33 0.29
FeNO (ppb) 18 (14e35) 18 (12e25) 0.47
Total sputum
cell number
(106/g)
0.7 (0.4e1.4) 0.7 (0.3e1.5) 0.92
Neutrophils (%) 63 (38e82) 63 (38e75) 0.47
Macrophages (%) 26 (14e46) 28 (16e41) 0.56
Lymphocytes (%) 2.7 (1.0e4.8) 1.5 (0.5e3.8) 0.20
Eosinophils (%) 0.0 (0.0e0.6) 0.2 (0.0e1.3) 0.08
Epithelial cells (%) 2.5 (0.8e6.7) 2.2 (1.0e5.2) 0.99
Results are expressed as mean  SD except for FeNO value,
sputum cell count and cell percentages, which are expressed as
median (IQR). BMI: body mass index, NMA: non-myeloablative
conditioning, MA: myeloablative conditioning, n Z non-
smoker, ex Z ex-smoker, cs Z current smoker, FEV1: forced
expiratory volume in 1 s; FVC: forced vital capacity; TLC: total
lung capacity; RV: residual volume; DLCO: diffusing capacity of
the lung for carbon monoxide; KCO: gas transfer coefficient;
FeNO: exhaled nitric oxide.
2078 C. Moermans et al.reported that low FEV1 and DLCO were associated with
poorer prognosis [40,41]. However, we recognise that lung
function impairment at baseline was rather mild in our
cohort. On the other hand, survival after HSCT has
dramatically improved over the last ten years [42] and the
potential disadvantage of small lung function impairment in
our series may have been compensated by the marked
improvement in the management of the post-transplant
period.Our study shows that patients who undergo HSCT
display mild progressive loss of total lung capacity asso-
ciated with sustained airway neutrophilic inflammation.
By contrast bronchiolitis obliterans syndrome rarely occurs
after HSCT.
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